Research programme: human papillomavirus vaccine - Biotech Australia/University of Queensland

Drug Profile

Research programme: human papillomavirus vaccine - Biotech Australia/University of Queensland

Latest Information Update: 30 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotech Australia; The University of Queensland
  • Class
  • Mechanism of Action Helper-inducer T-lymphocyte modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cervical cancer

Most Recent Events

  • 18 Nov 2002 No development reported - Preclinical for Cervical cancer in Australia (Parenteral)
  • 18 May 1999 A study has been added to the adverse events section and the Viral Infections immunogenicity section
  • 14 Sep 1998 Phase-I clinical trials for Cervical cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top